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Binding of hnRNP H to an exonic
splicing silencer is involved
in the regulation of alternative splicing
of the rat b-tropomyosin gene
Charlie Degui Chen,1,2 Ryuji Kobayashi,1 and David M. Helfman1,3
1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA; 2Molecular and Cellular Biology Program, State
University of New York at Stony Brook, Stony Brook, New York 11790 USA
In the rat b-tropomyosin (b-TM) gene, exons 6 and 7 are spliced alternatively in a mutually exclusive manner.
Exon 6 is included in mRNA encoding nonmuscle TM-1, whereas exon 7 is used in mRNA encoding skeletal
muscle b-TM. Previously, we demonstrated that a six nucleotide mutation at the 5* end of exon 7, designated
as ex-1, activated exon 7 splicing in nonmuscle cells. In this study, we show that the activating effect of this
mutation is not the result of creating an exonic splicing enhancer (ESE) or disrupting a putative secondary
structure. The sequence in exon 7 acts as a bona fide exonic splicing silencer (ESS), which is bound
specifically by a trans-acting factor. Isolation and peptide sequencing reveal that this factor is hnRNP H, a
member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family. Binding of hnRNP H correlates with
the ESS activity. Furthermore, addition of antibodies that specifically recognizes hnRNP H to the splicing
reactions or partial depletion of hnRNP H from nuclear extract activates exon 7 splicing in vitro and this
effect can be reversed by addition of purified recombinant hnRNP H. These results indicate that hnRNP H
participates in exclusion of exon 7 in nonmuscle cells. The involvement of hnRNP H in the activity of an ESS
may represent a prototype for the regulation of tissue- and developmental-specific alternative splicing.
[Key Words: RNA processing; cis-acting element; trans-acting factor; heterogeneous nuclear
ribonucleoproteins; RNA–protein interaction]
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Alternative RNA splicing is a common mechanism for
regulating gene expression in eukaryotes (for reviews,
see Adams et al. 1996; Wang et al. 1997; Ko¨nig et al.
1998). By this mechanism, a precursor mRNA (pre-
mRNA) transcribed from a single gene can be processed
to generate multiple mRNAs that are translated into
various protein isoforms, often with different functions
according to sex, tissue type, developmental stage, or
environmental cues. Thus, studies on the regulation of
alternative RNA splicing are essential for a complete un-
derstanding of gene expression at the molecular level.
One of the best-known examples demonstrating the
importance and regulation of alternative RNA splicing is
the genes involved in the Drosophila sex determination
pathway (for reviews, see Rio 1993; Wang et al. 1997).
The Sex lethal (Sxl) protein is produced in female flies,
where it binds to the regulatory element in intron 2 of
transformer pre-mRNA and leads to the production of
functional transformer protein (Tra) (Boggs et al. 1987;
Inoue et al. 1990; Valca´rcel et al. 1993). Tra, along with
the common splicing factor transformer 2 (Tra 2), binds
to the cis-acting element in exon 4 of doublesex pre-
mRNA (Hedley and Maniatis 1991; Hoshijima et al.
1991; Ryner and Baker 1991; Inoue et al. 1992; Tian and
Maniatis 1993). This binding recruits a set of SR pro-
teins, which are general splicing factors, thereby activat-
ing the 38 splice site upstream of exon 4 and giving rise to
the production of the female-specific doublesex mRNA
(Zahler et al. 1992; Tian and Maniatis 1993; Wu and
Maniatis 1993; Lynch and Maniatis 1995).
Although much less is known about the regulation of
alternative splicing in vertebrates, cis-acting regulatory
elements have been identified in both exon and intron
sequences. Regulatory intron sequences that activate or
inhibit splicing have been identified in several pre-
mRNAs, including b-tropomyosin (b-TM) (Helfman et
al. 1990; Libri et al. 1990; Guo et al. 1991; Sirand-Pugnet
et al. 1995), c-src (Black 1992), fibroblast growth factor
receptor (FGFR) (Gatto and Breathnach 1995), fibronec-
tin (Huh and Hynes 1994), calcitonin/calcitonin gene-
related peptide (Lou et al. 1995), and adenoviral pre-
mRNA (Kanopka et al. 1996). Exonic splicing enhancers
(ESEs) have also been shown to be involved in the regu-
lation of alternative RNA splicing and purine-rich ESEs
have been found in pre-mRNAs such as mouse immu-
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noglobulin M exon M2 (Watakabe et al. 1993), chicken
cardiac troponin T exon 5 (Xu et al. 1993), human fibro-
nectin EDA exon (Caputi et al. 1994), the last exon of
bovine growth hormone (Hampson et al. 1989), and rat
b-TM exon 8 (Tsukahara et al. 1994; Selvakumar and
Helfman 1998). In contrast, exonic splicing silencers
(ESSs) have been identified only in a few pre-mRNAs
such as fibronectin EDA exon (Caputi et al. 1994), hu-
man immunodeficiency virus (HIV)-tat exon 2 and tat-
rev exon 3 (Amendt et al. 1995; Staffa and Cochrane
1995), FGFR-2 K-SAM exon (Gatto and Breathnach
1995), bovine papillomavirus type 1 pre-mRNA (Zheng
et al. 1996), and cell surface molecule CD44 exon 5 (Ko¨-
nig et al. 1998). To date, only a few trans-acting factors
have been implicated in the regulation of alternative
splicing in vertebrates. SF2/ASF, a member of the SR
protein family, stimulates splicing from the proximal 58
splice sites in some pre-mRNAs (Ge and Manley 1990;
Krainer et al. 1990), whereas heterogeneous nuclear ri-
bonucleoprotein A1 (hnRNP A1) antagonizes this activ-
ity and stimulates splicing from the distal 58 splice sites
(Mayeda and Krainer 1992; Ca´ceres et al. 1994; Yang et
al. 1994). The activation of splicing by SR proteins is
presumably by binding to cis-acting elements such as
ESEs (Lavigueur et al. 1993; Sun et al. 1993; Ram-
chatesingh et al. 1995). SR proteins have also been
shown to inhibit adenovirus IIIa pre-mRNA splicing by
binding to an intronic repressor (Kanopka et al. 1996).
Another group of potential splicing regulators is the
hnRNP family of proteins. hnRNP I, also known as the
polypyrimidine tract binding protein (PTB), has been im-
plicated in the regulation of alternatively spliced pre-
mRNAs, such as b-TM (Mulligan et al. 1992), fibronectin
(Norton 1994), a-TM (Lin and Patton 1995; Perez et al.
1997; Gooding et al. 1998), r2 subunit of the GABA re-
ceptor (Ashiya and Grabowski 1997), and c-src (Chan and
Black 1997). Another member of the hnRNP family,
hnRNP F, along with a KH-type splicing regulatory pro-
tein (KSRP), binds to the downstream control sequence
(DCS) of c-src and activates splicing of the N1 exon (Min
et al. 1995, 1997).
We have been using rat b-TM pre-mRNA as a model
system to study the regulation of alternative RNA splic-
ing (Helfman et al. 1988, 1990; Helfman and Ricci 1989).
The rat b-TM gene consists of 11 exons, and 2 exon pairs
are alternatively spliced. Exons 6 and 11 are used for
generating TM-1 mRNA in nonmuscle cells, which also
corresponds to smooth muscle b-TM; exons 7 and 10 are
used for forming b-TM mRNA in skeletal muscle and
fetal cardiac muscle cells (Fig. 1A). Previous results from
our laboratory demonstrated that splicing of the skeletal
muscle-specific exon 7 in nonmuscle cells was blocked
in its 38 splice site (Guo and Helfman 1993). Two cis-
acting elements that are critical for blocking exon 7
splicing in nonmuscle cells were identified in sequences
at the 58 end of exon 7 and the 38 end of intron 6 [the
intron regulatory element (IRE)] (Helfman et al. 1990;
Guo et al. 1991; Guo and Helfman 1993). Mutations or
deletions of the IRE led to utilization of exon 7 in non-
muscle cells. Further studies indicated that PTB, as well
as other proteins, such as FUSE-binding protein (FBP)
and a homolog of human Sam 68 tyrosine phosphopro-
tein, formed a complex on the IRE that may be involved
in blocking the recognition of the 38 splice site of exon 7
(Mulligan et al. 1992; Grossman et al. 1998). We also
showed that a mutation, designated as ex-1, in which six
nucleotides UGUGGG at the 58 end of exon 7 were mu-
tated to GGAUCC (Fig. 1B), activated exon 7 splicing in
nonmuscle cells in vivo (Guo et al. 1991). These data
demonstrated that the sequence at the 58 end of exon 7
function as a cis-acting element regulating rat b-TM pre-
mRNA alternative splicing. However, the mechanism by
which these sequences contribute to the regulation of
splice site selection was not known.
In this report, we show that sequences at the 58 end of
exon 7 function as an ESS. The ubiquitously expressed
hnRNP H binds to this ESS, and its binding correlates
with the silencer activity. We demonstrate further that
the addition of antibodies, which recognize hnRNP H to
the splicing reactions or depletion of hnRNP H from
nuclear extract, activates exon 7 splicing in vitro, and
this activation is reversed by recombinant hnRNP H pro-
tein. Our data show for the first time that hnRNP H
participates in the negative regulation of alternative
RNA splicing and that hnRNP H is a trans-acting factor
involved in ESS activity in vertebrates.
Results
An in vitro system to study the ex-1 mutation
Our previous data demonstrated that a mutation at the
Figure 1. (A) A schematic diagram of rat b-TM gene. Boxes
represent exons and lines introns; shaded boxes represent tis-
sue-specific exons as indicated. (B) The wild-type and mutated
sequences of exon 7. Lowercase letters represent sequences in
adjacent introns, and +1 is the first nucleotide of exon 7. The
mutated sequences are indicated below the wild-type se-
quences. (C) Stem I of the putative secondary structure in the
wild-type substrate. (D) The restored stem I of the putative sec-
ondary structure when both complementary strands are mu-
tated simultaneously.
Chen et al.
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58 end of exon 7, designated as ex-1, reversed normal
exon selection in nonmuscle cells in vivo, resulting in
utilization of the skeletal muscle-specific exon 7 instead
of the nonmuscle-specific exon 6 (Guo et al. 1991). This
dramatic effect led us to hypothesize that sequences at
the 58 end of exon 7 may be an important cis-acting el-
ement in the regulation of rat b-TM pre-mRNA alterna-
tive splicing. By studying how this cis-acting element
functions, we may be able to reveal some of the general
principles of tissue- and developmental-specific regula-
tion of alternative splicing in vertebrates.
To study biochemically how the ex-1 mutation acti-
vates exon 7 splicing in nonmuscle cells, we first de-
signed a suitable pre-mRNA. Although we could have
used the minigene p2 that contains genomic sequences
from exon 5 to exon 9, the complexity of spliced prod-
ucts and the difficulty of detecting the effect of the ex-1
mutation in vitro (data not shown) counteracted the use-
fulness of this substrate (Helfman et al. 1988; Guo et al.
1991). Because exon 7 is not required for the complex
formation in intron 6 (Grossman et al. 1998), we pre-
dicted that the cis-acting element in exon 7 uses a dif-
ferent mechanism from the IRE at the 38 end of intron 6.
Thus, it is possible to study the involvement of exon 7
sequences in the regulation of rat b-TM pre-mRNA al-
ternative splicing independent of intron 6 sequences.
Consequently, a pair of simple RNA substrates, the wild-
type 5(5)7 and the mutant 5(5)7 ex-1, were generated.
Substrate 5(5)7 consists of exon 5, intron 5, and exon 7.
To simplify the nomenclature in this paper, an exon is
indicated by its number and an intron by its number
in parenthesis.
To determine the kinetics of splicing, the wild-type
and mutant substrates were subjected to in vitro splicing
reaction in a time course reaction. When the mutant
substrate was tested, the first step of splicing was de-
tected within 30 min of incubation, resulting in cleaved
exon 5 and the intermediate lariat (5)7 (Fig. 2, lane 6). As
the splicing reaction proceeded, the intensity of the in-
termediate lariat (5)7 decreased and the final product
5 + 7 increased (Fig. 2, lanes 7–10). The intensity of the
final lariat intron (5) decreased because it was degraded.
The wild-type substrate was not spliced even after 2.5 hr
of incubation (Fig. 2, lanes 1–5). These results suggest
that the mechanism involved in the cis-acting element
in exon 7 is independent of intron 6. Thus, the mecha-
nism responsible for the activation of the ex-1 mutation
can be studied using this pair of simple RNA substrates.
The sequence at the 58 end of exon 7 is an exonic
splicing silencer
Several possible mechanisms may be responsible for the
activation of the ex-1 mutation. One is that the muta-
tion creates an ESE, thereby activating exon 7 splicing in
nonmuscle cells. To test this possibility, we made two
other random mutations. One mutated UGUGGG to
CUACGC (ex-16), and the other mutated AAUGUG-
GGGA to UGUACGAUCG (ex-110) (see Fig. 1B). We
reasoned that if the activation of the ex-1 mutation is a
consequence of an ESE, the same effect should not be
seen with two other random mutations. However, these
two mutated substrates were also spliced (Fig. 3A, lanes
9–16); the ex-110 mutant was spliced more efficiently
than the ex-1 mutant (Fig. 3A, cf. lanes 13–16 with lanes
5–8), and the ex-16 mutant was spliced with the highest
efficiency (Fig. 3A, lanes 9–12). The band in the wild-
type substrate that migrated more slowly than the inter-
mediate lariate (5)7 is a prematurely transcribed RNA
(Fig. 3A, lanes 1–4). The possibility remains that all these
mutations create ESEs, with the ex-16 mutation being
the strongest one. However, combined with the data de-
scribed later, these data suggest that it is unlikely that
the activation of the ex-1 mutation is attributable to cre-
ation of an ESE.
The second possible mechanism by which the ex-1
mutation activates exon 7 splicing is by disrupting a sec-
ondary structure. A secondary structure was shown in
chicken b-TM pre-mRNA (D’Orval et al. 1991; Libri et
al. 1991), and stem I (see Fig. 1C) plays a key role in the
stabilization of this structure. A similar secondary struc-
ture was previously proposed for rat b-TM gene based on
computer predictions (Helfman et al. 1990). Because the
ex-1 mutation disrupts the formation of stem I, it is pos-
Figure 2. An in vitro system to study the ex-1 mutation. The
wild-type and ex-1 mutation 5(5)7 pre-mRNAs containing exon
5, intron 5, and exon 7 were synthesized and subjected to in
vitro splicing reactions using the conditions indicated at the
top. The RNAs were resolved on 4% polyacrylamide 8 M urea
gel and visualized by autoradiography. The precursors, interme-
diate, and final products are indicated at left.
hnRNP H and ESS in alternative splicing
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sible that this structure also participates in the regula-
tion of rat b-TM pre-mRNA alternative splicing. To test
this possibility, we mutated the complementary se-
quence ACCAACA to GGAAUCC to disrupt the puta-
tive secondary structure (ex-m) (see Fig. 1B). If the acti-
vation of the ex-1 mutation is attributable to the disrup-
tion of the putative secondary structure, the ex-m
mutation would also activate exon 7 splicing. However,
ex-m did not activate exon 7 splicing (Fig. 3B, lanes
9–12). Furthermore, when the putative secondary struc-
Figure 3. The 58 end of exon 7 contains an ESS. Transcription and
in vitro splicing were carried out as in Fig. 2, and the marker is the
same as in Fig. 2. (A) Activation of ex-1 does not result from cre-
ation of an ESE. The wild-type and mutant 5(5)7 substrates are
indicated at the top. (B) Activation of ex-1 mutation does not result
from disruption of the putative secondary structure. The wild-type
and mutant 5(5)7 substrates are indicated at the top. (C) Titration
experiments. Splicing reactions were carried out in the absence
(lanes 1,8,15,19) or presence of 10, 20, or 30 pmoles of the specific
competitor ECS, or nonspecific competitor WU as indicated. The
substrates are indicated at the top, the precursors and the products
on either side. 5(5)6 contains exon 6 instead of exon 7 in 5(5)7;
b-globin pre-mRNA consists of exon 1, intron 1, and exon 2 of the
human b-globin gene.
Chen et al.
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ture was reconstituted by simultaneously mutating both
complementary strands (ex-1/m) (see Fig. 1B), exon 7 was
spliced (Fig. 3B, lanes 13–16). The kinetics and intensi-
ties of exon 7 splicing were comparable between the ex-1
and ex-1/m mutants (Fig. 3B, cf. lanes 13–16 with lanes
5–8). These data indicated that the activation of the ex-1
mutation does not result from disruption of the putative
secondary structure.
The third possible mechanism responsible for the ac-
tivation of the ex-1 mutation is disrupting the binding of
trans-acting factors. If so, addition of the wild-type se-
quence to the splicing reaction should titrate away these
trans-acting factors and activate exon 7 splicing. When
an oligoribonucleotide ECS (ESS-Containing Sequence)
that contains a sequence from +2 to +19 of exon 7 was
added to the in vitro splicing reaction, the wild-type sub-
strate 5(5)7 was activated, and the activation increased
with an increasing amount of ECS (Fig. 3C, lanes 1–4).
The activation of exon 7 splicing was specific to ECS
because an unrelated oligoribonucleotide WU had no ef-
fect on the activation of exon 7 splicing (Fig. 3C, lanes
5–7). To determine whether the effect of ECS was spe-
cific to exon 7, we also added ECS to the splicing reac-
tions with a substrate 5(5)6. This substrate has exon 6 as
the downstream exon instead of exon 7 as in the sub-
strate 5(5)7. Addition of ECS did not activate exon 6
splicing (Fig. 3C, lanes 15–18) or stimulate the splicing
of the human b-globin pre-mRNA (Fig. 3C, lanes 19–
22). These results suggest that the binding of trans-
acting factors to sequences within exon 7 may be in-
volved in the regulation of rat b-TM pre-mRNA alterna-
tive splicing.
To confirm our conclusion, we tested the splicing of
the mutant substrate 5(5)7 ex-1 in titration experiments.
As shown in Figure 3A, the ex-1 mutation activates exon
7 splicing, but this activation is not the strongest; both
ex-110 and ex-16 activate exon 7 splicing stronger than
ex-1. If the inability of exon 7 to be spliced is attributable
to the binding of negative trans-acting factors, the failure
of the ex-1 mutation to reach maximal activation may be
because the ex-1 mutant still weakly associates with the
putative trans-acting factors. Therefore, addition of ECS
may also enhance splicing of 5(5)7 ex-1, which, indeed,
occurred (Fig. 3C, lanes 8–11). This activation was spe-
cific for ECS because addition of WU did not activate the
splicing of 5(5)7 ex-1 (Fig. 3C, lanes 12–14). We conclude
that the sequence UGUGGG at the 58 end of exon 7 is
part of an ESS, and that the binding of trans-acting fac-
tors is responsible for the activity of the ESS.
Specific proteins cross-link to the ESS sequences
To identify and characterize the trans-acting factors that
bind to the ESS, we performed UV cross-linking experi-
ments with uniformly G- and C-radiolabeled 20-mer
RNAs because all the mutations contain an equal
amount of G and C. When an oligoribonucleotide con-
taining the wild-type ESS sequence was used in UV
cross-linking experiments, a prominent UV cross-linked
product was identified (Fig. 4A, lane 1). This cross-linked
product was also detected when each of the mutated oli-
goribonucleotides was used (Fig. 4A, lanes 2–4), but the
amount of the product was much less than in the experi-
ment in which the wild-type was used (Fig. 4A, cf. lanes
2–4 with lane 1). The ex-110 mutation probably creates a
binding site for an unrelated protein, resulting in the
formation of a cross-linked product of <50 kD (Fig. 4A,
lane 4, bottom arrow). These results are consistent with
the conclusion that the ESS sequence is a binding site for
trans-acting factors.
To determine whether the cross-linked protein binds
specifically to the ESS and whether it binds more
strongly to the wild-type ESS than to the mutant se-
quences, we performed competition assays in the UV
cross-linking experiments. The product that cross-linked
to the wild-type sequence (Fig. 4B, lane 1) was gradually
competed away with an increasing amount of the wild-
type competitor (Fig. 4B, lanes 2–6), but not by a compa-
rable amount of either the mutant ex-110, or ex-1, or
ex-16 competitor (Fig. 4B, lanes 7–11; data not shown).
Taken together, these data suggest that at least one pro-
tein specifically binds to the ESS sequence and that its
Figure 4. A protein cross-links to the ESS. (A) 32P-Labeled oli-
goribonucleotide that contains either the wild-type or mutated
ESS as indicated at the top was cross-linked to HeLa cell nuclear
extract and resolved on a 10% SDS-polyacrylamide gel. Two
arrows indicate two cross-linked products in lane 4; the upper
one migrated similarly to the products in other lanes. (B) 32P-
Labeled oligoribonucleotide that contains the wild-type ESS
was cross-linked to HeLa cell nuclear extract in the absence
(lane 1) or presence of 10- , 20- , 40- , 60- , or 80-fold excess of the
wild-type competitor or mutant competitor ex-110 as indicated.
hnRNP H and ESS in alternative splicing
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binding may be responsible for the activity of the ESS in
exon 7.
hnRNP H binds to the ESS sequence
To identify the binding factor that specifically interacts
with the ESS sequence, we fractionated HeLa cell
nuclear extracts and assayed each fraction using UV
cross-linking to detect the interactions with the radiola-
beled oligonucleotide containing the wild-type ESS. The
majority of the protein was present in the 20%–50%
ammonium sulfate fraction (Fig. 5A, lane 2). The 60%–
90% fraction also gave rise to several cross-linked prod-
ucts (Fig. 5A, lane 4), which is not surprising because
the natural binding factor was not in this fraction and
the binding site of this protein is now available for
other proteins.
The 20%–50% ammonium sulfate fraction was used
to purify the protein by a biotin–streptavidin affinity as-
say. Accordingly, a biotin-labeled RNA containing six
tandem repeats of the ESS sequence was incubated with
the 20%–50% ammonium sulfate fraction, and the pro-
tein–RNA complexes were recovered by streptavidin–
agarose beads. The beads were washed, and the proteins
were eluted, resolved on SDS-polyacrylamide gels, and
visualized by silver staining. A 50-kD protein was well
separated on the gel (Fig. 5B, lane 1). The binding of this
protein could be competed away by the wild-type mono-
mer, but not by the ex-110 mutant (data not shown).
The biotin–streptavidin binding assay was scaled up;
the recovered proteins were separated by SDS-PAGE and
visualized by Coomassie blue G staining. The 50-kD pro-
tein band was excised from the gel, and subjected to in
gel digestion and microsequencing. One long peptide
with 22 amino acid residues (CC50K40) and a short pep-
tide (CC49K20) with 10 amino acid residues were ob-
tained (Fig. 5C). Database search revealed that these two
peptides were found in the sequence of hnRNP H (Hon-
ore´ et al. 1995).
Binding of hnRNP H correlates with the activity
of the ESS
To examine whether hnRNP H is involved in the activ-
ity of the ESS, we first carried out the biotin–streptavidin
affinity assay as described earlier except crude nuclear
extract was used in the place of the 20%–50% ammo-
nium sulfate fraction, and followed by Western blot
analysis to detect the possible interactions of hnRNP H
with the wild-type and different mutant 5(5)7 pre-
mRNAs. hnRNP H interacted strongly with the wild-
type substrate 5(5)7, as evidenced by recognition of the
50-kD band by a specific antibody against hnRNP H (Fig.
6A, lane 2). Binding of hnRNP H to exon 7 was specific
because substituting exon 6 for exon 7 virtually abol-
ished the binding (Fig. 6A, lane 1). hnRNP H also bound
to the mutant substrates of 5(5)7, but its apparent affin-
ity with the mutant substrates was weaker than with the
wild-type splicing substrate 5(5)7 (Fig. 6A, cf. lane 2 with
lanes 3–5).
To determine whether the binding of hnRNP H corre-
lates with the activity of the ESS, the wild-type and mu-
tant RNA competitors were used to compete the binding
of hnRNP H to the wild-type splicing substrate 5(5)7.
Addition of the wild-type RNA reduced the binding of
hnRNP H (Fig. 6B, lanes 2,3). The ex-1 competitor also
reduced this binding, but its relative competition effi-
ciency was weaker than that of the wild-type competitor
(Fig. 6B, lanes 4,5). The competition efficiency of ex-110
was even weaker than that of ex-1 (Fig. 6B, lanes 6,7), and
ex-16 was the weakest competitor (Fig. 6B, lanes 8,9).
These results indicate that the affinity of hnRNP H with
the various substrates (the wild type > ex-1 > ex-
110 > ex-16) correlates well with the silencer activities
of the different substrates (cf. Fig. 6A, lanes 2–5 with Fig.
3A), and suggest that hnRNP H is involved in the si-
lencer activity.
The hnRNP H antibody activates exon 7 splicing
in vitro
To further demonstrate that hnRNP H is involved in the
ESS activity, we performed antibody activation experi-
ments. We reasoned that if binding of hnRNP H to the
ESS is responsible for its activity, addition of anti-
Figure 5. Isolation and peptide-sequencing of hnRNP H. (A)
HeLa cell nuclear extracts were fractionated by ammonium sul-
fate precipitation, and each fraction was UV cross-linked to an
oligoribonucleotide containing the wild-type ESS. (B) The bio-
tinylated RNA (lane 1) or RNA (lane 2) containing six tandem
repeats of the wild-type ESS was incubated with the 20%–50%
ammonium sulfate fraction. The RNA–protein complexes were
pulled down by streptavidin–agarose. The proteins were eluted
with wash buffer containing 0.5 M KCl, resolved on a 10% SDS-
polyacrylamide gel, and visualized by silver staining. The arrow
indicates the 50-kD protein of interest. (C) Two peptides from
the 50-kD protein were obtained by peptide sequencing.
Chen et al.
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hnRNP H antibody may disrupt binding of hnRNP H to
the pre-mRNA or interaction of hnRNP H with other
proteins and, consequently, activate exon 7 splicing. As
shown in Figure 7, the wild-type substrate 5(5)7 was not
spliced under standard splicing conditions (Fig. 7, lane 1).
However, addition of anti-hnRNP H antibody activated
exon 7 splicing (Fig. 7, lane 2), and the activation was
stimulated in a dose dependent manner (Fig. 7, lane 3).
This activation was specific to the anti-hnRNP H anti-
body because addition of the preimmune serum had no
effect (Fig. 7, lanes 4,5). Also, the effect of the anti-
hnRNP H antibody was specific to exon 7 because sub-
strates 5(5)6 and the human b-globin pre-mRNA were
not activated by addition of the antibody (Fig. 7, lanes
11–16).
Because splicing of the ex-1 mutant was not fully ac-
tivated (see Fig. 3A), we were interested in determining
the effect of the anti-hnRNP H antibody on the splicing
of the mutant 5(5)7 ex-1. We reasoned that if the disso-
ciation of hnRNP H correlates with the activation of
exon 7 splicing, addition of anti-hnRNP H antibody will
further stimulate splicing of the ex-1 mutant, which in-
deed appeared to be the case (Fig. 7A, cf. lanes 7,8 with
lane 6). As addition of the preimmune serum had no
effect on splicing of the ex-1 mutation (Fig. 7A, lanes
9,10), the stimulation was specific to anti-hnRNP H an-
tibody. These results further support the notion that
hnRNP H binding is involved in the silencer activity.
Previously we have demonstrated that utilization of
exon 7 in nonmuscle cells is blocked at the upstream 38
splice site (Guo and Helfman 1993), and that the ex-1
mutation activates exon 7 splicing in nonmuscle cells in
vivo (Guo et al. 1991). Because the ex-1 mutation dis-
rupts binding of hnRNP H, we were interested in deter-
mining whether hnRNP H is directly involved in the
regulation of rat b-TM pre-mRNA alternative splicing.
Therefore, we carried out antibody activation experi-
ments using a substrate p2(7/8) that consists of exon 5,
intron 5, exon 6, intron 6, and the joined exons 7/8. The
splicing of p2(7/8) was inefficient in HeLa cell nuclear
extracts because the 38 splice site upstream of exon 7 is
blocked (Fig. 7, lane 17), which is consistent with our
previous results (Guo and Helfman 1993). Addition of
anti-hnRNP H antibody stimulated exon 7 splicing (Fig.
7, lanes 18,19). This activation probably takes place at
the 38 splice site, as both products 57/8 and 5(5)67/8
were enhanced. Again, addition of the preimmune serum
had no effect (Fig. 7, lanes 20,21). From these results, we
concluded that hnRNP H is involved in the regulation of
rat b-TM pre-mRNA alternative splicing.
Recombinant hnRNP H antagonizes activation
of splicing by anti-hnRNP H antibody
To confirm the conclusions derived from the antibody
activation experiments that hnRNP H is involved in the
Figure 6. hnRNP H specifically binds to the ESS. (A) Biotin–
streptavidin binding assay was carried out using the biotinyl-
ated wild-type and mutant 5(5)7, and 5(5)6 splicing substrates;
the gels were probed with anti-hnRNP H antibody and visual-
ized by ECL. (B) Competitive biotin–streptavidin binding assay.
Biotin–streptavidin binding assay was carried out using the bio-
tinylated wild-type 5(5)7 in the presence of 20 or 40 pmoles of
oligoribonucleotide containing either the wild-type or mutated
ESS, as indicated.
Figure 7. Anti-hnRNP H antibody specifically activates exon 7
splicing. In vitro splicing reactions were carried out using the
substrates indicated at the top in the absence (lanes 1,5,17) or
presence of 5 or 10 µg of anti-hnRNP H (a) or preimmune (p)
rabbit sera as indicated below the substrates. The splicing reac-
tion on lane 16 has 20 µg of anti-hnRNP H rabbit serum. Sche-
matic representations of the precursors and products are shown
on both sides. For clarity, the precursor and splicing products
for the human b-globin pre-mRNA are not indicated (see Fig. 3C
for reference).
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ESS activity and regulation of rat b-TM pre-mRNA al-
ternative splicing, we performed rescue experiments.
First we tested the splicing of wild-type 5(5)7 substrate,
which was activated by the anti-hnRNP H antibody (Fig.
8, lane 2). When recombinant glutathione S-transferase
(GST)–hnRNP H fusion protein was added to the splicing
reaction, the activation by anti-hnRNP H antibody de-
creased (Fig. 8, lane 3). Addition of an increasing amount
of the recombinant protein resulted in complete repres-
sion of exon 7 splicing (Fig. 8, lanes 4,5). This effect was
attributable to the hnRNP H protein because addition of
bovine serum albumin (BSA) or recombinant GST pro-
tein had no effect (Fig. 8, lanes 6–9). Also, recombinant
GST–hnRNP H had no effect on splicing of the human
b-globin pre-mRNA (Fig. 8, lanes 10–12). We also carried
out rescue experiments using p2(7/8) as a splicing sub-
strate. Addition of recombinant GST–hnRNP H protein
repressed almost completely the stimulatory effect of
anti-hnRNP H antibody on splicing of p2(7/8) (Fig. 8,
lanes 14–17). The repression resulted from the hnRNP H
protein because addition of BSA or recombinant GST had
no effect (Fig. 8, lanes 18–21).
Depletion of hnRNP H activates splicing of exon 7
The results of antibody activation and recombinant pro-
tein add-back experiments strongly suggest that hnRNP
H is involved in the suppression of exon 7 usage in non-
muscle cells. However, it is possible that the antibody
against hnRNP H titrated away other nuclear compo-
nents that are critical for the suppression of exon 7 us-
age, and the addition of recombinant hnRNP H released
these components and led to the resuppression of exon 7
splicing in nonmuscle cells.
To establish fully that hnRNP H is involved directly in
the suppression of exon 7 usage in nonmuscle cells, we
performed a depletion experiment using the polyclonal
antibody that was used in the activation experiment, and
carried out a splicing experiment using the depleted ex-
tract. This antibody is specific to hnRNP H, as it recog-
nized a single band in Western blot when HeLa cell
nuclear extract was tested (Fig. 9A, lanes 1–3). About
85% of hnRNP H was depleted from HeLa cell nuclear
extract (Fig. 9A, lanes 4,6,8), comparing to the mock
depletion (Fig. 9A, lanes 5,7,9). The antibody specifically
depleted hnRNP H from HeLa cell nuclear extract, as the
concentration of PTB in the depleted extract was not
changed (Fig. 9A).
To examine functionally the depleted extracts, we per-
formed an in vitro splicing experiment using p2(7/8) as a
substrate. The splicing of p2(7/8) was weak in the mock-
depleted extract (Fig. 9B, lane 1). However, the utiliza-
tion of the 38 splice site of exon 7 was significantly
stimulated in the antibody-depleted extract, as evi-
denced by the production of an increasing amount of
both products 57/8 and 5(5)67/8 (Fig. 9B, lane 2). This
stimulation is specific because antibody or mock deple-
tion of hnRNP H had no effect on the splicing of the
human b-globin pre-mRNA (Fig. 9C, lanes 1,2). To de-
termine whether the stimulation of the 38 splice site
usage of exon 7 is attributable to the depletion of hnRNP
H, we performed a recombinant protein add-back experi-
ment. Addition of 0.3 µg of recombinant GST–hnRNP H
to the depleted extract reduced the splicing of p2(7/8)
about threefolds (Fig. 9B, lane 3). The resuppression re-
sulted from the addition of hnRNP H because addition of
recombinant GST or PTB had no effect (Fig. 9B, lanes
6–9). However, the splicing of exon 7 was not completely
resuppressed even when a higher concentration of re-
combinant hnRNP H was added in splicing reactions
(Fig. 9B, lanes 4,5), which suggests that modification of
hnRNP H may be required or some other factors may be
involved. Addition of GST–hnRNP H to the depleted ex-
tract had no effect on the splicing of the human b-globin
(Fig. 9C, lanes 3,4). Collectively, these results indicate
that hnRNP H is involved directly in the suppression of
exon 7 splicing in nonmuscle cells.
Discussion
The 58 end of the skeletal muscle exon 7 contains
an ESS
Previous data from our laboratory showed that a muta-
tion at the 58 end of exon 7, designated as ex-1, activated
exon 7 splicing in nonmuscle cells in vivo (Guo et al.
Figure 8. Recombinant hnRNP H antagonizes the activation
of anti-hnRNP H antibody. In vitro splicing reactions were car-
ried out in the absence (lanes 1,13) or presence of 10 µg of anti-
hnRNP H rabbit serum, and in the presence of 0.2, 0.4, or 0.6 µg
of recombinant GST–hnRNP H (G-H), 0.3 or 0.6 µg of recombi-
nant GST (G), and 0.3 or 0.6 µg of BSA as indicated. The sub-
strates are indicated at the top, and schematic representations of
the precursors and splicing products are shown on both sides.
For clarity, the precursor and splicing products for the human
b-globin pre-mRNA are not indicated (see Fig. 3C for reference).
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1991). In this report we show that activation of the ex-1
mutation is neither attributable to creation of an ESE nor
to disruption of a putative secondary structure, but
rather results from disruption of an ESS that contains the
sequence UGUGGG.
Several ESSs have been identified in various mamma-
lian pre-mRNAs (Caputi et al. 1994; Amendt et al. 1995;
Gatto and Breathnach 1995; Staffa and Cochrane 1995;
Zheng et al. 1996; Ko¨nig et al. 1998). The ESS identified
in exon 7 of rat b-TM pre-mRNA probably functions
through repression of the 38 splice site of skeletal
muscle-specific exon because that is the major blocking
site to repress utilization of exon 7 in nonmuscle cells
(Guo and Helfman 1993). Furthermore, addition of anti-
hnRNP H antibody to p2(7/8) splicing reactions stimu-
lated the splicing of two spliced products: 57/8 and
5(5)67/8, both of which use the same 38 splice site up-
stream of exon 7. The ability of an ESS to exert repres-
sion on its upstream 38 splice site is a common feature
for the ESSs identified in mammals, as is the require-
ment for a weak 38 splice site. The ESS in exon 7 requires
a weak 38 splice site for its function because only a sub-
strate with intron 5 or intron 6 of rat b-TM pre-mRNA,
but not intron 1 of the human b-globin pre-mRNA or the
modified intron 2 of a-TM pre-mRNA with an upstream
sequence insertion, can mimic the behavior of the ex-1
mutation (Fig. 2; data not shown). Analysis of exon 7
sequence revealed that, adjacent to the ESS, exon 7 con-
Figure 9. Depletion of hnRNP H activates the splicing of exon 7. (A) Depletion of hnRNP H from HeLa cell nuclear extract. Western
blot analysis was carried out with 1, 2, and 4 µg of untreated (lanes 1–3), antibody-depleted (lanes 4,6,8), and mock depleted extract
(lanes 5,7,9), probed with anti-hnRNP or anti-PTB antibodies as indicated. (B) Splicing of p2(7/8) in mock-depleted extract (lane 1), or
hnRNP H depleted extract without (lane 2) or with increasing amount (0.3, 0.6, and 0.9 µg) of recombinant GST–hnRNP H (lanes 3–5),
recombinant GST (0.3 and 0.9 µg, lanes 6,7), or recombinant PTB (0.3 and 0.9 µg, lanes 8,9). (C) Splicing of the human b-globin
pre-mRNA in mock-depleted extract (lane 1), hnRNP H-depleted extract without (lane 2), or with 0.3 and 0.9 µg of recombinant
GST–hnRNP H (lanes 3,4).
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tains a purine-rich element, GAGGAGGAG, that is
identical to well-characterized ESEs (Watakabe et al.
1993; Xu et al. 1993). This bipartite architecture may
represent a general feature for ESSs to participate in the
regulation of alternative splicing because most of the
ESSs identified to date share this structure (Amendt et al.
1995; Staffa and Cochrane 1995; Zheng et al. 1996; Ko¨nig
et al. 1998). In most cases, ESSs are located downstream
of ESEs. However, the ESS in exon 7 lies immediately
upstream of the putative ESE. This kind of bipartite
structure was also recently identified in exon 5 of the
cell surface molecule CD44 (Ko¨nig et al. 1998).
hnRNP H is a splicing regulator
By using UV cross-linking method, we identified a trans-
acting factor of ~ 50 kD that binds to the ESS in exon 7 of
rat b-TM pre-mRNA. Isolation and microsequencing
showed that this protein is hnRNP H. The correlation
between the binding of hnRNP H and the ESS activity
suggests that hnRNP H is involved in the regulation of
the ESS in exon 7, which was confirmed both by anti-
body activation/add-back experiments, and by deple-
tion/add-back experiments. The involvement of hnRNP
H in the regulation of alternative splicing may not be
surprising, as hnRNP F has been shown to participate in
the formation of a multiprotein complex in the DCS of
c-src and play a critical role in the regulation of c-src
alternative splicing (Min et al. 1995), and hnRNP H and
F are highly homologous; their protein sequences are
78% identical (Honore´ et al. 1995). Other members of
the hnRNP family have also been implicated in the regu-
lation of alternative splicing of several mammalian pre-
mRNAs. For example, hnRNP A1 was shown to antago-
nize the effect of SF2/ASF to promote the distal 58 splice
site usage (Mayeda and Krainer 1992; Yang et al. 1994).
hnRNP I, also known as PTB, participates in the regula-
tion of pre-mRNA alternative splicing of a-TM, b-TM,
and others. In contrast to other members of the hnRNP
family that bind to intron sequences, hnRNP H binds to
an exon sequence in vertebrates.
hnRNP H was first identified by two-dimensional gel
electrophoresis analysis (Dreyfuss et al. 1993), and the
corresponding cDNA has been isolated and characterized
(Honore´ et al. 1995). The hnRNP H cDNA is predicted to
encode a protein with three RNA binding domains
(RBD). This protein has a high binding affinity for
poly(rG) (Matunis et al. 1994; Honore´ et al. 1995), which
suggests that hnRNP H may be involved in splicing of
other transcripts besides rat b-TM pre-mRNA. The ESS
in the FGFR-2 K-SAM exon is also a guanine-rich ele-
ment TAGGGCAGGC (Gatto and Breathnach 1995). An
intronic G-rich sequence (A/U)GGG has been impli-
cated in the regulation of chicken b-TM pre-mRNA al-
ternative splicing (Sirand-Pugnet et al. 1995), and an in-
tron splicing enhancer (ISE) containing a G-rich repeat
has been shown to facilitate the inclusion of a micro-
exon in chicken troponin T pre-mRNA (Carlo et al.
1996). It will be interesting to determine whether
hnRNP H also binds to these sequences and is respon-
sible for their activities. Indeed, hnRNP H was recently
identified to be involved in the formation of a multipro-
tein complex that is required for the activation of the N1
exon splicing in c-src (D.L. Black, pers. comm.).
hnRNP H is involved in the regulation of rat b-TM
pre-mRNA alternative splicing
The 38 splice site upstream of exon 7 is the major site to
block utilization of exon 7 in nonmuscle cells (Guo and
Helfman 1993). Two cis-acting elements are involved in
this block: the IRE located at the 38 end of intron 6 was
shown to be critical for blocking the utilization of exon
7 in nonmuscle cells and this blocking may involve bind-
ing of a multiprotein complex (Helfman et al. 1990; Guo
et al. 1991; Mulligan et al. 1992; Grossman et al. 1998).
Another cis-acting element involved is the sequence at
the 58 end of exon 7 because mutation of this element
activates exon 7 splicing in nonmuscle cells (Guo et al.
1991). In this report, we demonstrate that the sequence
at the 58 end of exon 7 is a bona fide ESS. Addition of
anti-hnRNP H antibody or depletion of hn RNP H acti-
vated exon 7 splicing to produce both products 57/8 and
5(5)67/8, and recombinant hnRNP H antagonized this
activation. These results make hnRNP H a good candi-
date for the repressor that recognizes the ESS at the 58
end of exon 7, and suggest that hnRNP H is involved
directly in the regulation of rat b-TM pre-mRNA alter-
native splicing.
Our previous data demonstrated that the sequences in
exon 7 are not required for the formation of the protein
complex that appears to be involved in the activity of the
IRE (Grossman et al. 1998), and the data in this report
indicate that the cis-acting element in exon 7 that blocks
utilization of exon 7 is not dependent on the specific
sequences of intron 6. These results suggest that two
independent mechanisms operate simultaneously to
block exon 7 usage in nonmuscle cells; disrupting either
of these mechanisms leads to the release of the block and
utilization of exon 7. Thus, it is reasonable to speculate
that different tissue types or tissues at different develop-
mental stages may use different mechanisms to release
the suppression of exon 7. For example, fetal cardiac
muscle may disrupt the complex formation in intron 6
and skeletal muscle may reduce binding of hnRNP H to
exon 7 sequence, or vice versa. It will be interesting to
determine which mechanisms are used in different cell
types during embryonic development.
Several possible mechanisms may account for how
hnRNP H blocks the utilization of exon 7 in nonmuscle
cells. For example, the binding of hnRNP H may displace
the association of SR proteins with exon 7 because a
putative ESE is located immediately downstream of the
ESS. Thus, binding of hnRNP H to the ESS may sterically
interfere with binding of SR proteins to the ESE. When
the ESS is mutated, binding of hnRNP H is down regu-
lated and SR proteins may now bind to the ESE. This
model is consistent with our data that the 60%–90%
ammonium sulfate fraction of HeLa cell nuclear extract
gave rise to several cross-linked products because SR pro-
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teins are present in this fraction (Fig. 5A). It remains to
be determined whether these cross-linked products are
SR proteins.
How hnRNP H participates in the regulation of tissue-
and developmental-specific alternative splicing remains
to be answered. Using either nucleic acid or immuno-
logical probes, we did not detect any difference in the
expression levels of hnRNP H mRNA or protein in vari-
ous mouse tissues at different developmental stages
(data not shown). Thus, tissue-specific changes in the
expression levels of hnRNP H do not appear to be in-
volved in the regulation. One possibility is that addi-
tional factors are involved; these factors are tissue spe-
cific and function together with hnRNP H in regulation
of alternative RNA splicing. This kind of mechanism is
used in the regulation of doublesex alternative splicing
in Drosophila, where both tra, a female-specific factor,
and tra 2, which is expressed in both sexes, are required
for the female-specific splicing (McKeown 1992). Also, in
P-element alternative splicing, both PSI, a somatic cell-
specific factor, and hrp 48, an ubiquitously expressed
protein, are needed to repress intron 3 splicing (Rio
1993). Furthermore, skeletal muscle cells may possess a
different isoform of hnRNP H because several isoforms
of this protein has been identified (B. Honore´, pers.
comm.). As each of the three RNA-binding domains of
hnRNP H has also strong affinity with poly(rG) (Honore´
et al. 1995), different isoforms may exhibit different af-
finities for the ESS in exon 7. Another possibility is tis-
sue-specific phosphorylation, as phosphorylation has
been shown to affect binding of hnRNP C to pre-mRNA
(Mayrand et al. 1993), and hnRNP H can be phosphory-
lated (Honore´ et al. 1995). Experiments are currently
under way to further study how hnRNP H affects the
ESS activity and what determines the basis for the tis-
sue-specific regulation of rat b-TM pre-mRNA alterna-
tive splicing.
Materials and methods
Oligonucleotides
Oligonucleotides used for PCR to generate the splicing sub-
strates are as follows:
PCR(1), 58-GATTTAGGTGACACTATAG; PCR(2), 58-AAC-
TGCAGGCAGGGGGCAGCGGGCAT; PCR(3), 58-CAGCTG-
CAGTAAATGTGGGGACC; PCR(4), 58-CAGCTGC-AGTAA-
AGGATCCGACCTAGAGGAGGAGCT; PCR(5), 58-CAGCT-
GCAGTAAACTACGCGACCTAGAGGAGGAGCT; PCR(6), 58-
CAGCTGCAGTATGTACGATCGCCTAGAGGAGGAGCTG-
AA; PCR(7), 58-CGGAATTCCTTGTCCGCTTGGGCTTCCAC;
PCR(8), 58-CGGAATTCCTTGTCCGCTTGGGCTTCCAGA-
GATTTCAAGTGGATTCCAACAATTTTCAGCTCCTCCT.
The oligonucleotides used to generate the oligoribonucleo-
tides for UV cross-linking experiments and competition in bi-
otin–streptavidin binding assays are as follows: UV(1), 58-
AATTTAATACGACTCACTATAG; UV(2), 58-TCTAGGTC-
CCCACATTTCCCTATAGTGAGTCGTATTAAATT; UV(3),
58-TCTAGGTCGGATCCTTTCCCTATAGTGAGTCGTATT-
AAATT; UV(4), 58-TCTAGGTCGCGTAGTTTCCCTATAGT-
GAGTCGTATTAAA-TT; UV(5), 58-TCTAGGCGATCGTAC-
ATCCCTATAGTGAGTCGTATTAAATT.
The oligodeoxynucleotides used to generate the six-tandem
repeats of the ESS sequence are as follows: ESS(1), 58-GATCT-
GCAGAAATGTGGGGACCTAGAGAAATGTGGGGACCTA-
GAG; ESS(2), 58-GATCCTCTAGGTCCCCACATTTCTCTA-
GGTCCCCACATTTCTGCA.
The oligoribonucleotides used in titration experiments are as
follows: ECS, 58GGAAAUGUGGGGACCUAGA, in which
three nucleotides at both ends are 28-O-methyl-modified; WU,
58CGUAUACCCUUGAC, in which two nucleotides at both
ends are 28-O-methyl-modified.
Plasmid constructions
The parental plasmid for all of the splicing substrates is pSP64,
which contains an SP6 promoter. To make the wild-type and
mutant 5(5)7 substrates, we first constructed a plasmid p5(5)
that contains exon 5 and intron 5. To maintain a PstI site in the
construct, the fragment was PCR amplified using PCR(1) and
PCR(2) as primers and p2(7/8) (Helfman and Ricci 1989) as the
template, and was then digested with HindIII and PstI. This
construct maintains the length of intron 5, but has a mutation
from CC to TG in intron 5 four nucleotides from the 58 end of
the downstream exon. The resulting mutation does not affect
the recognition of the downstream AG dinucleotide in splicing.
For the construction of the plasmids containing the wild-type,
ex-1, ex-16, and ex-110 5(5)7s, PCR using p2(7/8) as the tem-
plate and PCR(7) with either PCR(3), PCR(4), PCR(5), or PCR(6)
as primers, respectively, was performed and each PCR product
was inserted into the p5(5) plasmid. To construct 5(5)7 ex-m and
5(5)7 ex-1/m, PCR using p2(7/8) as the template and PCR(8)
with either PCR(3) or PCR(4) as primers, respectively, was per-
formed, and each PCR product was inserted into the plasmid
p5(5). The sequences of all mutations were confirmed by DNA
sequence analysis and are shown in Figure 1.
The plasmid for expressing GST–hnRNP H in Escherichia
coli was constructed by inserting the full-length hnRNP H
cDNA into pRP265, a derivative of pGEX-2T that has a GST tag.
The full-length hnRNP H cDNA was obtained from pT7-
PL-TOT (Honore´ et al. 1995) by a partial digestion using BamHI
and EcoRI.
Preparation and fractionation of HeLa cell nuclear extracts
HeLa cell nuclear extracts were prepared as described (Dignam
et al. 1983; Krainer et al. 1984). For fractionation of HeLa cell
nuclear extracts by ammonium sulfate precipitation, 2 ml of
extract was first diluted with 8 ml of buffer D without both
glycerol and KCl. Ammonium sulfate was gradually added to
the nuclear extract to 20% of saturation. After 30 min of stirring
at 4°C, the extract was centrifuged in an H-6000A rotor (Sorvall)
at 6000g at 4°C for 20 min to obtain 0%–20% ammonium sul-
fate fraction, and the resulting supernatant was transferred to a
fresh beaker. The same procedure was repeated to obtain the
subsequent 20%–50%, 50%–60%, and 60%–90% ammonium
sulfate fractions. The fractions were resuspended and dialyzed
against buffer D. The remaining supernatant was concentrated
in a microconcentrator (Amicon) and dialyzed against buffer D.
The 2-ml extract yielded 1 ml of 0%–20% fraction, 2 ml of
20%–50% fraction, 1 ml of 50%–60% fraction, 2 ml of 60%–
90% fraction, and 200 µl of supernatant.
Purification of recombinant proteins
and antibody preparation
A fresh colony of E. coli BL21 transformed with plasmids con-
taining GST or GST–hnRNP H cDNA was grown in 5 ml of
Luria–Bertani (LB) medium containing ampicillin (amp) at 37°C
hnRNP H and ESS in alternative splicing
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for 12 hr. The culture was transferred to 500 ml of LB + amp and
grown to OD600 = 0.1 at 37°C. Isopropyl-b-D-thiogalactopyrano-
side (IPTG) was added to reach concentration of 0.5 mM and the
culture was grown for another hour. The bacteria were har-
vested, resuspended in 10 ml of freshly made 50% urea solution
supplemented with 5 mM dithiothreitol (DTT), and incubated at
65°C for 1 hr with vigorous vortexing every 10 min. The bacte-
rial lysate was clarified by centrifugation at 10,000g, and the
supernatant was dialyzed in buffer [20 mM Tris (pH 8.0), 0.1 mM
EDTA, 1 mM DTT, 5% glycerol, 60 mM KCl]. After clarification,
the supernatant was loaded onto a glutathione–Sepharose 4B
column and washed with PBS (140 mM NaCl, 2.7 mM KCl, 10
mM Na2HPO4, and 1.8 mM KH2PO4). The bound protein was
eluted with 10 mM glutathione in 10 mM HEPES (pH 8.0), and
dialyzed with buffer D.
The purified GST–hnRNP H protein was sent to COVANCE
Research Products Inc. for antibody production in rabbits. Sera
(491 and 492) from two rabbits were obtained, and each had a
protein concentration of ~ 60 µg/ml. Both sera recognized re-
combinant GST–hnRNP H and a major protein corresponding to
hnRNP H in HeLa cell nuclear extracts (data not shown). Both
sera precipitated a protein corresponding to hnRNP H from
HeLa cell nuclear extracts and gave rise to exclusive nuclear
signals in immunofluorescence staining (data not shown). Be-
cause 492 had a higher titer than 491 in Western blot analysis,
it was used for studies in this report.
Splicing substrate preparation, in vitro splicing,
and immunodepletion assays
The plasmids used as templates for the splicing substrates were
linearized with the appropriate restriction enzymes, and tran-
scribed by SP6 polymerase as described (Helfman et al. 1988). In
vitro splicing reactions were carried out at 30°C for 2 hr unless
otherwise indicated. Standard splicing conditions used for these
studies consist of 15 µl of HeLa cell nuclear extracts in a final
reaction volume of 25 µl containing 2 mM MgCl2, 0.5 mM ATP,
20 mM creatine phosphate, 15 ng of pre-mRNA, 12.8 mM HEPES
(pH 8), 14% (vol/vol) glycerol, 60 mM KCl, 0.12 mM EDTA, and
0.3 mM DTT. In some reactions, 1 or 3 mM MgCl2 was used
instead of 2 mM MgCl2, and some reactions contained 2.5%
polyvinyl alcohol (PVA). For titration and antibody activation
experiments, the reaction mixtures without pre-mRNA were
preincubated with an RNA competitor or an antibody, respec-
tively, at 30°C for 10 min, and then the pre-mRNA was added to
proceed the splicing reaction. To antagonize the activation of
anti-hnRNP H antibody, the reaction mixtures without pre-
mRNA were preincubated with a recombinant protein or BSA
and the antibody at 30°C for 10 min, and then the pre-mRNA
was added to proceed the splicing reaction.
Immunodepletion and add-back experiments were performed
as described (Zuo and Maniatis 1996). Briefly, 0.5 ml of protein
A–Sepharose beads (Pharmacia) were incubated with 1 ml of
anti-hnRNP H or preimmune serum (mock) for 2 hr at 4°C. The
beads were washed twice with 10 ml of buffer D with 0.05%
Triton X-100 and without glycerol (wash buffer), packed into a
minicolumn, and equilibrated with 10 ml of buffer D. Six hun-
dred microliters of HeLa cell nuclear extract was passed through
the column four times at 4°C, and the eluate was passed
through a fresh protein A column (0.5 ml in bed volume) twice
to remove residual antibody. The antibody- and mock-depleted
HeLa cell nuclear extracts were tested for concentration of
hnRNP H and PTB by Western blotting, and used directly in
standard splicing experiments. For add-back experiments, re-
combinant proteins were added to the depleted extracts and the
splicing reactions were assembled.
Preparation of oligoribonucleotides and UV
cross-linking experiments
The wild-type, ex-1, ex-16, and ex-110 oligoribonucleotides
were synthesized using oligonucleotides UV(1) with either
UV(2), UV(3), UV(4), or UV(5), respectively, as templates; the
transcription was conducted as instructed using the MEGA-
shortscriptTM T7 Kit (Ambion). For UV cross-linking experi-
ments, the RNA probes were synthesized in the presence of
[a-32P]CTP and [a-32P]GTP (3000 Ci/mmole). The reactions
were assembled in a 96-well plate in a final reaction volume of
12.5 µl containing 20,000 cpm of 32P-labeled probe, 8 µl HeLa
cell nuclear extract, either fractionated with ammonium sulfate
precipitation or nonfractionated, 2 mM MgCl2, 0.5 mM ATP, 20
mM creatine phosphate, 0.2 mg/ml tRNA, and 0.016 mg/ml
BSA. After incubation at 30°C for 10 min, the reaction mixtures
were irradiated at 4°C with 254 nm UV light at a distance of 4.5
cm from the source for 10 min. The RNA molecules in the
reaction mixtures were digested at 37°C with RNase A (1 mg/
ml) and RNase T1 (2.5 U/µl) for 10 min. The reaction mixture
was boiled in SDS loading buffer, resolved on a 10% SDS-poly-
acrylamide gel, and visualized by autoradiography. In competi-
tion experiments, the competitor was also included in the re-
action mixture.
Preparation of biotinylated RNA and biotin–
streptavidin-binding assay
The biotinylated RNAs were synthesized as instructed using
the MEGAscript™ SP6 Kit (Ambion). Two micrograms of bio-
tin-labeled RNA was mixed with 10 µl of HeLa cell nuclear
extract containing 0.05% Triton X-100 and 1 mg/ml heparin.
After incubation on ice for 30 min, 20 µl of solution that con-
tains 10 µl of packed streptavidin–agarose was added. The reac-
tion mixture was shaken at 4°C for another 30 min and washed
with buffer D with 0.05% Triton X-100 and without glycerol
(wash buffer). The bound proteins were resolved in 10% SDS-
polyacrylamide gel, Western blotted using anti-hnRNP H anti-
body, and visualized by enhanced chemiluminescence (ECL).
For competition experiments, the oligoribonucleotide competi-
tor was synthesized as described earlier. The competitor was
preincubated with the reaction mixture on ice for 30 min and
then the biotin-labeled RNA was added to proceed the reaction.
Isolation and peptide sequencing of hnRNP H
The isolation of hnRNP H followed the protocol of biotin–strep-
tavidin binding assay except that the 20%–50% ammonium
sulfate fraction was used instead of HeLa cell nuclear extracts.
The bound proteins were eluted with wash buffer containing 0.5
M KCl, concentrated in a microconcentrator (Amicon), resolved
on a 10% SDS-polyacrylamide gel, and visualized by either sil-
ver or Coomassie Brilliant Blue G staining. The 50-kD protein
was carefully excised from the gel and subjected to in-gel diges-
tion using Achromobacter protease I in 50 µg/ml in 50 mM
Tris-HCl (pH 9.0) as described previously (Wang et al. 1996).
The resulting polypeptides were separated by HPLC using a
Vydac C18 column (1.0 × 250 mm, 10 µm, 300 Å) and sequenced
by automated protein sequencers (Applied Biosystems 494).
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